Kymera Therapeutics (KYMR) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall Street mixed as oil prices surge, investors await earnings, economic data
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts KYMR Hot Sheet
Join SI Premium – FREE
Kymera Therapeutics (NASDAQ: KYMR) reported Q1 EPS of ($0.69), $0.02 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $10.3 million versus the consensus estimate of $13.78 million.
For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SolarMax Technology (SMXT) Misses Q2 EPS by 98c
- Truist Securitas's Biotechnology Earnings Preview: 'INSM, BBIO, NBIX Most Levered to the Print'
- UBS Reiterates Buy Rating on Chipotle Mexican Grill (CMG), Sees Likelihood of Starbucks Transaction as 'Somewhat Low'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
